Century Therapeutics Inc. (IPSC:NASDAQ) was just greenlighted by the U.S. Food and Drug Administration (FDA) to evaluate CNTY-101 in patients with relapsed or refractory CD19 positive B-cell malignancies, and the company plans to start a Phase 1 trial of this lead cell therapy candidate this year," reported H.C. Wainwright & Co. analyst Mitchell Kapoor in an August 26, 2022 research note.
CNTY-101 is one of Century's iPSC-derived natural killer cell therapies with four complementary functions, including tumor targeting.
"This represents a major milestone for Century, as this is the first investigational new drug clearance of a product candidate that utilizes Century's common iPSC progenitor, which is to be used across the pipeline," Kapoor wrote.
As such, the analyst pointed out, the successful development of CNTY-101 would establish proof of concept for the biopharma's platform and its Allo-Evasion technology.
"Allo-Evasion edits differentiate [the company's] natural killer and T-cell therapy approaches by allowing evasion of and elimination by the host immune system, which should enhance pharmacokinetics and eventually duration, in our view," noted Kapoor.
The impending Phase 1 trial, called ELiPSE-1, is designed to assess the safety, tolerability, pharmacokinetics, and efficacy of CNTY-101 in patients with relapsed or refractory, CD19 positive, aggressive lymphoma, or indolent lymphoma after receiving two or more lines of treatment including CAR-T cell therapy, Kapoor described. Initial data from the study could be available by late 2023.
Along with the commencement of ELiPSE-1, upcoming catalysts for Century, according to Kapoor, include the company:
1) Holding a research and development day to discuss preclinical data from its gamma delta solid tumor platform (in the fall)
2) Releasing preclinical data from its gamma delta T-cell platform (in Q4/22)
3) Unveiling a solid tumor candidate program (in Q4/22)
4) Choosing a candidate based on its iPSC-derived natural killer cell therapy platform (by year-end)
H.C. Wainwright has a Buy rating and a target price of $27 per share on Century Therapeutics, the current share price of which is around $10.18.
|Want to be the first to know about interesting Biotechnology / Pharmaceuticals investment ideas? Sign up to receive the FREE Streetwise Reports' newsletter.||Subscribe|
1) Doresa Banning wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. As of the date of this article, an affiliate of Streetwise Reports has a consulting relationship with: None. Please click here for more information.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the decision to publish an article until three business days after the publication of the article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.
Disclosures For H.C.Wainwright & Co., Century Therapeutics Inc., Aug. 26, 2022
H.C. Wainwright & Co, LLC (the “Firm”) is a member of FINRA and SIPC and a registered U.S. Broker-Dealer.
I, Mitchell S. Kapoor and Raghuram Selvaraju, Ph.D. , certify that 1) all of the views expressed in this report accurately reflect my personal views about any and all subject securities or issuers discussed; and 2) no part of my compensation was, is, or will be directly or indirectly related to the specific recommendation or views expressed in this research report; and 3) neither myself nor any members of my household is an officer, director or advisory board member of these companies.
None of the research analysts or the research analyst’s household has a financial interest in the securities of Century Therapeutics, Inc. (including, without limitation, any option, right, warrant, future, long or short position). As of July 31, 2022 neither the Firm nor its affiliates beneficially own 1% or more of any class of common equity securities of Century Therapeutics, Inc..
Neither the research analyst nor the Firm knows or has reason to know of any other material conflict of interest at the time of publication of this research report.
The research analyst principally responsible for preparation of the report does not receive compensation that is based upon any specific investment banking services or transaction but is compensated based on factors including total revenue and profitability of the Firm, a substantial portion of which is derived from investment banking services.
The firm or its affiliates received compensation from Century Therapeutics, Inc. for non-investment banking services in the previous 12 months. The Firm or its affiliates did not receive compensation from Century Therapeutics, Inc. for investment banking services within twelve months before, but will seek compensation from the companies mentioned in this report for investment banking services within three months following publication of the research report.
The Firm does not make a market in Century Therapeutics, Inc. as of the date of this research report. The securities of the company discussed in this report may be unsuitable for investors depending on their specific investment objectives and financial position. Past performance is no guarantee of future results. This report is offered for informational purposes only, and does not constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such would be prohibited. This research report is not intended to provide tax advice or to be used to provide tax advice to any person. Electronic versions of H.C. Wainwright & Co., LLC research reports are made available to all clients simultaneously.
H.C. Wainwright & Co., LLC does not provide individually tailored investment advice in research reports. This research report is not intended to provide personal investment advice and it does not take into account the specific investment objectives, financial situation and the particular needs of any specific person. Investors should seek financial advice regarding the appropriateness of investing in financial instruments and implementing investment strategies discussed or recommended in this research report.
H.C. Wainwright & Co., LLC’s and its affiliates’ salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies that reflect opinions that are contrary to the opinions expressed in this research report.
H.C. Wainwright & Co., LLC and its affiliates, officers, directors, and employees, excluding its analysts, will from time to time have long or short positions in, act as principal in, and buy or sell, the securities or derivatives (including options and warrants) thereof of covered companies referred to in this research report. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data on the company, industry or security discussed in the report. All opinions and estimates included in this report constitute the analyst’s judgment as of the date of this report and are subject to change without notice.
Securities and other financial instruments discussed in this research report: may lose value; are not insured by the Federal Deposit Insurance Corporation; and are subject to investment risks, including possible loss of the principal amount invested.